A global leading cause of death is cardiovascular disease (CVD), and this is often linked to a number of abnormalities in the arterial system. Numerous clinical, in vivo, and in vitro studies are ongoing to better understand various forms of CVD and to find ways to combat it. Although studying cells of the cardiovascular system in vitro has led to many discoveries, it is a challenge to study explanted cells because they do not grow well and lose specificity. However, researchers found that a combination of two transcription factors, MYCN and SOX17, can induce and indeﬁnitely expand cultured human arterial endothelial cell precursors that are derived from CD34+ stem cells.
Severe and prolonged neutropenia is a common consequence of cancer chemotherapy and is associated with an increased risk of severe infections. Transfusion of donor neutrophils is a viable option to combat this, but obtaining matched donors is a dilemma. There are pharmacologic interventions aimed at shortening the duration of neutropenia and combatting infection; however, infection risk remains high due to a lack of response to these treatments in many patients.
Dilated cardiomyopathy occurs when the heart muscle stretches and becomes weakened, leading to less efficient pumping of the blood throughout the body. It is the most common form of non-ischemic cardiomyopathy (not due to coronary artery disease). Dilated cardiomyopathy may be associated with damage to the heart muscle from a variety of causes such as inflammation, infections, and toxic substances. Diastolic dysfunction seen in patients with dilated cardiomyopathy refers to insufficient relaxation and filling of the ventricles during the second part of the heart-pumping phase (leading to increased pressure in the ventricles).
The leading cause of death for U.S. citizens is cardiovascular disease, which affects nearly a third of the U.S. population. There is an active and dedicated search for effective therapies to address this serious medical issue. The use of immunotherapy approaches for a number of diseases and conditions is continuously gaining momentum. Included in this is the use of CD34+ stem cells from a patients’ own blood (autologously derived) to treat cardiovascular disease. CD34+ is derived from bone marrow and other tissue types. However, CD34+ stems cells are more widely known for their hematopoietic origin.
Insulin-like growth factors (IGFs) are hormones resembling insulin and are important for normal cell growth and division. IGF-binding proteins (IGFBPs) regulate IGF action leading to changes in their effects in the body. IGF-binding protein-3 (IGFBP-3) is the most abundant of the IGFBPs and is made primarily in kupffer cells (specialized liver macrophages).